Marleox
Antibacterial drug for systemic use. After administration of single and repeated doses of 500 mg, the mean volume of distribution of levofloxacin is approximately 100 liters, indicating its wide distribution in body tissues.
One tablet contains:
active substance: levofloxacin hemihydrate 512.46 mg (equivalent to 500.0 mg levofloxacin).
excipients: microcrystalline cellulose, hydroxypropyl cellulose, crospovidone, magnesium stearate, hypromellose, FD&C blue 2 aluminum lacquer, FD&C yellow 6 aluminum lacquer, iron oxide red (E 172), polyethylene glycol, titanium dioxide, iron oxide yellow (E 172).
Adult patients for the treatment of the following infections:
- acute bacterial sinusitis
- exacerbation of chronic obstructive pulmonary disease, including bronchitis
- complicated skin and soft tissue infections.
In the above diseases, Marleox should be used only in cases where it is impossible to use the usually recommended antibacterial drugs for the initial treatment of these diseases.
- acute pyelonephritis and complicated urinary tract infections
- chronic bacterial prostatitis
- uncomplicated cystitis
- pulmonary anthrax: post-exposure prophylaxis and radical treatment.
Marleox tablets can also be used to continue treatment in patients who have improved after initial therapy with intravenous levofloxacin.
National guidelines for the use of antibacterial drugs should be followed.
Tablets are taken orally 1 or 2 times a day. The daily dose depends on the disease, the severity of its course, as well as the sensitivity of the alleged pathogen.
Marleox 500 mg tablets can also be used to continue the treatment of patients who have improved after initial therapy with levofloxacin for intravenous administration. Given the bioequivalence of parenteral and oral forms, the same dosage can be prescribed.
Composition
One tablet contains:
active substance: levofloxacin hemihydrate 512.46 mg (equivalent to 500.0 mg levofloxacin).
excipients: microcrystalline cellulose, hydroxypropyl cellulose, crospovidone, magnesium stearate, hypromellose, FD&C blue 2 aluminum lacquer, FD&C yellow 6 aluminum lacquer, iron oxide red (E 172), polyethylene glycol, titanium dioxide, iron oxide yellow (E 172).
Indications for use
Adult patients for the treatment of the following infections:
- acute bacterial sinusitis
- exacerbation of chronic obstructive pulmonary disease, including bronchitis
- complicated skin and soft tissue infections.
In the above diseases, Marleox should be used only in cases where it is impossible to use the usually recommended antibacterial drugs for the initial treatment of these diseases.
- acute pyelonephritis and complicated urinary tract infections
- chronic bacterial prostatitis
- uncomplicated cystitis
- pulmonary anthrax: post-exposure prophylaxis and radical treatment.
Marleox tablets can also be used to continue treatment in patients who have improved after initial therapy with intravenous levofloxacin.
National guidelines for the use of antibacterial drugs should be followed.
Mode of application
Tablets are taken orally 1 or 2 times a day. The daily dose depends on the disease, the severity of its course, as well as the sensitivity of the alleged pathogen.
Marleox 500 mg tablets can also be used to continue the treatment of patients who have improved after initial therapy with levofloxacin for intravenous administration. Given the bioequivalence of parenteral and oral forms, the same dosage can be prescribed.